Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
GlobeNewswire
Company announcement – No. 27 / 2024
*Zealand Pharma announces topline results from the mechanistic investigator-led..